Professor Richard Price
Contact information
Research groups
Ethiopian Clinic
Vietnam Hospital
Richard Price
Professor of Tropical Medicine
- Wellcome Clinical Fellow, Asia Pacific, Australia
Vivax malaria
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with 15 malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- define the direct and indirect morbidity and mortality of vivax malaria
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria,
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN) and co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
CURRENT PROJECTS:
- Clinical trials of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Ex vivo drug susceptibility of novel antimalarial compounds
Timika, Papua, Indonesia
RSMM Hospital
Sumatra Site for IMPROV Study
Ex vivo Lab
Key publications
-
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price RN. et al, (2014), The Lancet Infectious Diseases, 14, 982 - 991
-
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price RN. et al, (2004), The Lancet, 364, 438 - 447
-
Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia
Tjitra E. et al, (2008), PLoS Medicine, 5, e128 - e128
-
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study
Douglas NM. et al, (2017), PLOS Medicine, 14, e1002379 - e1002379
-
The effect of dose on the antimalarial efficacy of artemether–lumefantrine: a systematic review and pooled analysis of individual patient data
(2015), The Lancet Infectious Diseases, 15, 692 - 702
-
The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data
(2013), PLoS Medicine, 10, e1001564 - e1001564
Recent publications
-
Identifying and combating the impacts of COVID-19 on malaria
Rogerson SJ. et al, (2020), BMC Medicine, 18
-
Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asia–Pacific region
Noviyanti R. et al, (2020), Malaria Journal, 19
-
The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study
Dini S. et al, (2020), BMC Medicine, 18
-
Towards harmonization of microscopy methods for malaria clinical research studies
Dhorda M. et al, (2020), Malaria Journal, 19
-
The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
Hossain MS. et al, (2020), PLOS Medicine, 17, e1003393 - e1003393
-
The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia
Thriemer K. et al, (2020), PLOS Neglected Tropical Diseases, 14, e0008838 - e0008838